Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients - Wikidata - awgldk - TriplyDB

Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients

Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients

http://www.wikidata.org/entity/Q28258349

about

Ubiquitin-proteasome system involvement in Huntington's disease Mutant ubiquitin found in Alzheimer's disease causes neuritic beading of mitochondria in association with neuronal degeneration Mutant ubiquitin (UBB+1) associated with neurodegenerative disorders is hydrolyzed by ubiquitin C-terminal hydrolase L3 (UCH-L3)The HECT domain of TRIP12 ubiquitinates substrates of the ubiquitin fusion degradation pathway Pathways towards and away from Alzheimer's disease Age-related gene-specific changes of A-to-I mRNA editing in the human brain Presenilin binding protein is associated with neurofibrillary alterations in Alzheimer's disease and stimulates tau phosphorylation Transcriptional slippage in bacteria: distribution in sequenced genomes and utilization in IS element gene expression It Is All about (U)biquitin: Role of Altered Ubiquitin-Proteasome System and UCHL1 in Alzheimer Disease The Ubiquitin-Proteasome System: Potential Therapeutic Targets for Alzheimer's Disease and Spinal Cord Injury Misframed ubiquitin and impaired protein quality control: an early event in Alzheimer's disease Ribosomal frameshifting and transcriptional slippage: From genetic steganography and cryptography to adventitious use Heritable change caused by transient transcription errors Structural Basis of E2-25K/UBB+1 Interaction Leading to Proteasome Inhibition and Neurotoxicity Alternatively spliced isoforms of FE65 serve as neuron-specific and non-neuronal markers The Ubiquitin-Proteasome System and Molecular Chaperone Deregulation in Alzheimer's Disease Phosphorylation of the histone deacetylase 7 modulates its stability and association with 14-3-3 proteins Argyrophilic grain disease The ubiquitin-proteasome system in Alzheimer's disease Regulatory mechanisms involved in the control of ubiquitin homeostasis Translational misreading: a tRNA modification counteracts a +2 ribosomal frameshift The ubiquitin-proteasome pathway and proteasome inhibitors The ubiquitin proteasome system in glia and its role in neurodegenerative diseases Top-down proteomics with mass spectrometry imaging: a pilot study towards discovery of biomarkers for neurodevelopmental disorders The ubiquitin-proteasome pathway: on protein death and cell life Spermidine protects against α-synuclein neurotoxicity.Transgenic mice overexpressing reticulon 3 develop neuritic abnormalities.Neurofibrillary pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein.A survey of RNA editing in human brain Unexpected frameshifts from gene to expressed protein in a phage-displayed peptide library A dinucleotide deletion in amyloid precursor protein (APP) mRNA associated with sporadic Alzheimer's disease results in efficient secretion of truncated APP isoforms from neuroblastoma cell cultures.Novel subtractive transcription-based amplification of mRNA (STAR) method and its application in search of rare and differentially expressed genes in AD brains.Role of the ubiquitin proteasome system in Alzheimer's disease.Disease-associated mutant ubiquitin causes proteasomal impairment and enhances the toxicity of protein aggregates.Misincorporation by RNA polymerase is a major source of transcription pausing in vivo Tau interactome mapping based identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo.Genetic risk factors in Alzheimer's disease The study of genetic polymorphisms related to serotonin in Alzheimer's disease: a new perspective in a heterogenic disorder.Selective Transgenic Expression of Mutant Ubiquitin in Purkinje Cell Stripes in the Cerebellum.APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis

P2860

Q7863795-bc0367f5-441f-f615-0789-e83c231bc998

P805

Q21129327-9498DE00-9EBF-4A20-9615-4A1E0DA457D8 Q24311376-E3A0092F-EE02-4D8A-9E73-74EB09CBAB1C Q24314548-BECD0B60-42F6-4300-9C04-77A88B0FAC13 Q24317229-8DEB71E8-5040-41D4-9B34-B78B63718F49 Q24596270-93B74C09-44DD-4A0A-AB0B-5E62BEC030FC Q24597534-E1C3D233-9D68-4DFA-899A-CDA8D950C017 Q24670296-5C28D2BE-79B3-4787-B9E6-8227101B28C4 Q24797334-00739363-D348-4236-841E-832769977F34 Q26765816-88292140-4549-4BF5-A933-928AA793C641 Q26767879-22B43807-5594-434D-B89A-9927CA9065C9 Q26782999-38DB3B31-19E1-464E-A74A-3E2561373527 Q26970809-51D79857-89EF-4197-8802-A9DCFB8BB322 Q27321679-4AA867D4-7000-4A2C-9ED1-0DEDE9D331AF Q27664383-709A4241-6A29-4792-936D-6AA0C8536421 Q28137903-5CC8B4D3-717E-4A40-A612-48A500964242 Q28254943-1D92E23D-B363-46CF-ACDF-BDCAE3449FA4 Q28263821-CD670E8D-95A5-4BAD-A16D-3D10AA3DE2D8 Q28266563-9FD37931-A8A0-4D67-BE79-596C733CC265 Q28268311-ECAA1BED-E653-4C82-A55F-9B9A495F4A79 Q28280583-BEEC7E18-EB38-46E6-967D-5A4C0DE68397 Q28349567-145FE912-0CA9-45FD-B015-29F86EA8C917 Q28367002-150F9B6E-CF9D-4061-BA45-7CD23300BF96 Q28391948-5F8C655B-759F-4861-8C51-93EACA6AFD47 Q28542079-9A134AD3-150F-479E-A6E1-D9A5AC0A609C Q29619270-0D04CFA9-D880-4C99-8F9C-EDE20BB236D5 Q30369463-F1686C7B-89CB-4488-8677-9EAC32E98E66 Q30479560-7BBD1554-3360-49A2-B3D6-490F2E76BE0D Q30986723-CA347F63-2A35-42C5-92A8-9FA6AAB51018 Q31127917-4F714CB3-E642-4830-88EF-70A2F18096F4 Q32021997-E9E18A12-BED8-49B9-BA79-D19F94C07D9D Q32134036-D8D12E5C-D648-42CA-B9AE-DEF0C130B5C7 Q33262929-67100914-BAE4-4C85-90ED-812A5E8ECACC Q33307872-2316173D-BE34-45EC-89E9-707C5443DA42 Q33408783-40A6AFF7-155E-4F7F-BACD-19C7A9280491 Q33554229-66B75297-59A3-4466-B4C5-1367C0F61705 Q33559307-B254C47F-2F96-4837-A3C0-224055D23E26 Q33588353-71F90EB1-A2C9-4F76-B5AF-751DC1F8C4B0 Q33646729-036F0005-C3A6-4F49-8860-13EC106935C3 Q33665458-85D63B74-6CF1-4F76-95B4-F178C6869C67 Q33759956-ADAE3ADF-E79D-432A-9059-24B2418C77F6

P2860

Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients

http://www.wikidata.org/entity/Q28258349

description

1998 nî lūn-bûn

@nan

1998 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

1998 թվականի հունվարին հրատարակված գիտական հոդված

@hy

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

name

Frameshift mutants of beta amy ...... Alzheimer's and Down patients

@ast

Frameshift mutants of beta amy ...... Alzheimer's and Down patients

@de

Frameshift mutants of beta amy ...... Alzheimer's and Down patients

@en

Frameshift mutants of beta amy ...... Alzheimer's and Down patients

@fr

Frameshift mutants of beta amy ...... Alzheimer's and Down patients

@nl

type

label

Frameshift mutants of beta amy ...... Alzheimer's and Down patients

@ast

Frameshift mutants of beta amy ...... Alzheimer's and Down patients

@de

Frameshift mutants of beta amy ...... Alzheimer's and Down patients

@en

Frameshift mutants of beta amy ...... Alzheimer's and Down patients

@fr

Frameshift mutants of beta amy ...... Alzheimer's and Down patients

@nl

prefLabel

Frameshift mutants of beta amy ...... Alzheimer's and Down patients

@ast

Frameshift mutants of beta amy ...... Alzheimer's and Down patients

@de

Frameshift mutants of beta amy ...... Alzheimer's and Down patients

@en

Frameshift mutants of beta amy ...... Alzheimer's and Down patients

@fr

Frameshift mutants of beta amy ...... Alzheimer's and Down patients

@nl

P1433

Q28258349-3C168542-EE00-435A-88A7-207DA3283972

P1476

Q28258349-5BA9478E-9CBF-448E-A207-88893B3A53AA

P2093

Q28258349-28B9A637-453B-4056-BC16-58019B9D9AAD

Q28258349-3B919415-484F-44A4-BBC4-658680049D12

Q28258349-4CDB3192-2A86-466A-9DBE-AFD4C3AC4F5C

Q28258349-4F1BDE06-5FDC-46B6-A0F3-EBB522859DB6

Q28258349-6646DFB6-750A-4EAD-BC7B-08E6063D930D

Q28258349-6C8F9CA2-CC72-4AC7-8F55-52AD3BCAF1AC

Q28258349-78809BCC-4776-4B13-9A09-609CFCF3754A

Q28258349-8DEBB0BD-2B5D-4962-B5FE-38D041A4A40D

Q28258349-91B83506-323C-4D23-B911-2D0178E47ED9

Q28258349-B3A63A02-5F70-4CE5-B12D-F183E2D712A7

P304

Q28258349-1CC4ABC4-E19E-440A-924A-53C44D49871A

P31

Q28258349-A76D9569-52CA-4918-A9E1-675F9258379E

P3181

Q28258349-BEC39CB1-B9BF-46C8-8E7C-D2BCBF89826B

P356

Q28258349-9F286867-9933-45DE-91E4-8C0614B42AEB

P407

Q28258349-A0173102-34FB-4601-992F-11E74DE62B16

P433

Q28258349-100E5C18-1DEF-4012-90EB-CEE6796D1E73

P478

Q28258349-F8282156-B2DB-497E-B40A-E3ACA21BA3C1

P50

Q28258349-1F5CA774-B844-4288-89F4-094621A4B9F5

Q28258349-55487F60-BCC9-4B35-BF4F-7FA83136153B

P577

Q28258349-24DF55B2-6636-42D5-AADF-D92BD439AB0E

P5875

Q28258349-2A529265-39AF-4758-9C15-6238BA6EC7FF

P698

Q28258349-DAA5984E-2F79-474B-9773-B0337662F3D5

P921

Q28258349-1C94B746-E21C-43B9-B504-3DAF774DB75A

Q28258349-BC328091-7303-45C8-867D-5BF34822159B

P3181

P356

SCIENCE.279.5348.242

P1433

P1476

Frameshift mutants of beta amy ...... Alzheimer's and Down patients

@en

P2093

A Neubauer

http://www.w3.org/2001/XMLSchema#string

D P de Kleijn

http://www.w3.org/2001/XMLSchema#string

F G Grosveld

http://www.w3.org/2001/XMLSchema#string

F W van Leeuwen

http://www.w3.org/2001/XMLSchema#string

G J Martens

http://www.w3.org/2001/XMLSchema#string

H Burbach

http://www.w3.org/2001/XMLSchema#string

H H van den Hurk

http://www.w3.org/2001/XMLSchema#string

J A Sluijs

http://www.w3.org/2001/XMLSchema#string

J Peter

http://www.w3.org/2001/XMLSchema#string

M A Sonnemans

http://www.w3.org/2001/XMLSchema#string

P304

242-247

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4187723

http://www.w3.org/2001/XMLSchema#string

P356

10.1126/SCIENCE.279.5348.242

http://www.w3.org/2001/XMLSchema#string

P407

P433

5348

http://www.w3.org/2001/XMLSchema#string

P478

279

http://www.w3.org/2001/XMLSchema#string

P50

P577

1998-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235242292

http://www.w3.org/2001/XMLSchema#string

P698

9422699

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease